Former FDA adviser: 'No good evidence' that approved Alzheimer's treatment works | The Hill: Healthcare Policy

Harvard professor of medicine Aaron Kesselheim, a former member of the Food and Drug Administration's (FDA) advisory committee who left after a controversial new Alzheimer's disease drug was approved, spoke out Monday, saying research on the...